PTEN, a key tumor suppressor, is frequently downregulated in NSCLC, leading to hyperactivation of the PI3K/AKT/mTOR pathway and promoting progression, stemness, and therapy resistance (Luongo et al., 2019[87]). The gene discussed is PTEN; the disease is neoplasm.